BVXV
Income statement / Annual
Last year (2022), BiondVax Pharmaceuticals Ltd.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2022, BiondVax Pharmaceuticals Ltd.'s net income was -$531,000.00.
See BiondVax Pharmaceuticals Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$0.00
|
$2.75 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$2.75 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$5.77 M
|
$10.34 M
|
$16.00 M
|
$68.65 M
|
$19.09 M
|
$18.78 M
|
$7.79 M
|
$7.91 M
|
$5.49 M
|
$5.45 M
|
| General & Administrative
Expenses |
$0.00
|
$23.98 M
|
$16.14 M
|
$9.35 M
|
$5.09 M
|
$4.75 M
|
$4.06 M
|
$3.26 M
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
-$10.95 M
|
$0.00
|
-$3.72 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$5.30 M
|
$23.98 M
|
$5.19 M
|
$9.35 M
|
$1.37 M
|
$4.75 M
|
$4.06 M
|
$3.26 M
|
$2.65 M
|
$2.19 M
|
| Other Expenses |
$0.00 |
$509,000.00 |
-$23.47 M |
$352,000.00 |
$65,000.00 |
$130,000.00 |
$48,000.00 |
$133,000.00 |
$2.65 M |
$2.19 M |
| Operating Expenses |
$11.06 M |
$34.83 M |
-$2.28 M |
$78.35 M |
$20.46 M |
$23.66 M |
$11.90 M |
$11.30 M |
$8.14 M |
$7.64 M |
| Cost And Expenses |
$11.06 M |
$34.83 M |
-$2.28 M |
$78.35 M |
$20.46 M |
$23.66 M |
$11.90 M |
$11.30 M |
$8.14 M |
$7.64 M |
| Interest Income |
$5.27 M |
$3,000.00 |
$1.20 M |
$4,000.00 |
$779,565.00 |
$18,000.00 |
$55,000.00 |
$11,000.00 |
$0.00 |
$0.00 |
| Interest Expense |
-$5.27 M |
$10.83 M |
$4.86 M |
$14.92 M |
$3.61 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$562,000.00
|
$2.39 M
|
$2.44 M
|
$1.49 M
|
$260,000.00
|
$440,000.00
|
$621,000.00
|
$628,000.00
|
$677,000.00
|
$709,000.00
|
| EBITDA |
-$10.50 M
|
-$32.44 M
|
$3.48 M
|
-$76.86 M
|
-$19.68 M
|
-$12.30 M
|
-$11.28 M
|
-$10.68 M
|
-$7.47 M
|
-$6.93 M
|
| EBITDA Ratio |
0 |
-11.81 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
-12.67
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$5.27 M
|
-$5.15 M
|
-$2.43 M
|
-$30.84 M
|
$0.00
|
-$10.90 M
|
$2.72 M
|
$1.10 M
|
$378,000.00
|
-$395,000.00
|
| Income Before Tax |
-$5.80 M |
-$39.98 M |
-$1.39 M |
-$109.19 M |
-$23.29 M |
-$34.55 M |
-$9.18 M |
-$10.20 M |
-$7.76 M |
-$8.04 M |
| Income Before Tax Ratio
|
0
|
-14.55
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$5.27 M |
$10.83 M |
-$8.20 M |
$14.92 M |
$2.89 M |
$10.90 M |
-$55,000.00 |
-$11,000.00 |
$0.00 |
$0.00 |
| Net Income |
-$531,000.00 |
-$50.81 M |
$6.82 M |
-$124.11 M |
-$23.29 M |
-$34.55 M |
-$9.18 M |
-$10.20 M |
-$7.76 M |
-$8.04 M |
| Net Income Ratio |
0 |
-18.49 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
0 |
-36 |
6.15 |
-151.98 |
-35.64 |
-68.75 |
-27.19 |
-38.66 |
-23.76 |
-24.59 |
| EPS Diluted |
0 |
-36 |
6.15 |
-151.98 |
-35.64 |
-68.75 |
-27.19 |
-38.66 |
-23.76 |
-24.59 |
| Weighted Average Shares
Out |
$754.08 B
|
$1.41 M
|
$1.11 M
|
$816,629.00
|
$653,549.00
|
$502,577.00
|
$337,743.00
|
$263,807.00
|
$326,743.00
|
$326,743.00
|
| Weighted Average Shares
Out Diluted |
$754.08 B
|
$1.41 M
|
$1.11 M
|
$816,629.00
|
$653,549.00
|
$502,577.00
|
$337,743.00
|
$263,807.00
|
$326,743.00
|
$326,743.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
